BRIEF-Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc

MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc.

MAIA

0.00

July 8 (Reuters) - Maia Biotechnology Inc MAIA.A:

  • MAIA BIOTECHNOLOGY REPORTS STRONG INITIAL EFFICACY DATA IN THIRD-LINE NON-SMALL CELL LUNG CANCER FROM PHASE 2 THIO-101 PART C EXPANSION TRIAL

  • MAIA BIOTECHNOLOGY - ATEGANOSINE PLUS CEMIPLIMAB SHOWS ACCEPTABLE SAFETY PROFILE IN HEAVILY PRE-TREATED PATIENTS

  • MAIA BIOTECHNOLOGY - THIO-101 PART C SHOWS 90.5% DISEASE CONTROL RATE IN 3L NSCLC

  • MAIA BIOTECHNOLOGY - ATEGANOSINE PLUS CEMIPLIMAB OUTPERFORMS STANDARD CHEMOTHERAPY DCR IN 3L NSCLC

Source text: ID:nGNX49klM5

Further company coverage: MAIA.A


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.